In this article, we will look at the 15 Best Affordable Stocks to Buy According to Analysts.

On December 24, Kevin Mahn, President and CIO of Hennion & Walsh Asset Management, appeared on a CNBC Television interview to discuss his market outlook for 2026. He noted that 2025 has been a phenomenal year, with 41 record high closes for the S&P 500, resulting in a total return of around 18%. Moreover, the market also reached a 3-year anniversary of the bull market. Mahn believes that 2026 is going to be another bull market year, but with much more volatility. He expects 2026 to deliver another double-digit growth, but with certain areas of the market performing better than others. Mahn highlighted that these are going to perform well driven by increased capital expenditure over the past 2 years. They include the AI, AI infrastructure, aerospace and defense, biotech, and energy companies that are powering the AI.

Similar to most of the analysts, Mahn also believes that 2026 will be the year of diversification. He noted that the “Mag Seven” influence on the S&P 500 has been weakening. He elaborated that 2 years ago the Mag Seven constituted 62% of the total returns of the index, last year the contribution declined to around 52%, and for 2025 the current returns are around 44% of the index. Mahn further elaborated that the double-digit growth will be driven by earnings expansion and increased spending. However, he sees the valuation multiples largely staying the same as in 2025.

With that, let’s take a look at the 15 Best Affordable Stocks to Buy According to Analysts.

Our Methodology

To curate the list of 15 Best Affordable Stocks to Buy According to Analysts, we used the Finviz Stock Screener, Seeking Alpha, CNN, and Insider Monkey’s Q3 2025 hedge funds database as our sources. Using the Screener, we aggregated a list of stocks trading below the FWD P/E of 15 and for which analysts expect more than 25% upside. Next, we cross-checked the P/E ratios from Seeking Alpha and Upside Potential from CNN, and ranked the stock in ascending order of the upside potential. Lastly, we have also added the hedge fund sentiment around each stock sourced from Insider Monkey’s database. Please note that the data was recorded on December 24, 2025.

​Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).

15 Best Affordable Stocks to Buy According to Analysts

15. Sanofi (NASDAQ:SNY)

Forward P/E Ratio: 10.61

Number of Hedge Fund Holders: 32

Analyst Upside Potential: 26.14%

Sanofi (NASDAQ:SNY) is one of the Best Affordable Stocks to Buy According to Analysts. On December 24, Sanofi (NASDAQ:SNY) announced entering into a definitive agreement to acquire Dynavax Technologies Corporation (NASDAQ:DVAX), a company that has a marketed hepatitis B vaccine and a differentiated shingles vaccine candidate.

Management noted that the acquisition aligns with the company’s strategy by expanding its presence in adult immunization through Dynavax’s candidates. Moreover, HEPLISAV-B is the only two-dose adult hepatitis B vaccine approved in the US. The drug is administered in two monthly doses for faster protection compared to three-dose competitors over six months.

The deal is valued at $15.50 per share in cash, which totals to roughly $2.2 billion in equity value. Moreover, the deal has already been unanimously approved by the Dynavax board of directors and is expected to close in the first quarter of 2026. Management noted that this deal will not impact Sanofi’s (NASDAQ:SNY) financial guidance for 2025.

That said, Wall Street has a positive outlook on the stock, with analysts’ 12 month price target reflecting more than 26% upside from the current level. Recently, on December 17, Steve Scala from TD Cowen reiterated a Hold rating on the stock with a price target of $57.

Sanofi (NASDAQ:SNY) is a global healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions across pharmaceuticals, vaccines, and consumer healthcare.

14. PVH Corp. (NYSE:PVH)

Forward P/E Ratio: 6.32

Number of Hedge Fund Holders: 31

Analyst Upside Potential: 30.61%

PVH Corp. (NYSE:PVH) is one of the Best Affordable Stocks to Buy According to Analysts. PVH Corp. (NYSE:PVH) has fallen more than 21% since its fiscal Q3 2025 earnings release on December 3. However, Wall Street maintains a positive outlook on the stock, with analysts’ 12 month price target reflecting more than 30.6% upside from the current level.

Recently, on December 19, Dana Telsey from Telesy Advisory downgraded the stock from Outperform to Market Perform and also lowered the price target from $95 to $82. However, earlier on December 11, Jay Sole from UBS reiterated a Buy rating on the stock with a price target of $148.

During the fiscal Q3 2025, PVH Corp. (NYSE:PVH) grew its revenue by 1.74% year-over-year to $2.29 billion, surpassing expectations by $12.83 million. Moreover, the EPS of $2.83 also topped expectations by $0.29. Management noted that the growth was driven by disciplined execution of its PVH+ plan. Moreover, the company experienced growth in key categories, including underwear and fashion denim.

Jay Sole from UBS noted that he projects the company to deliver double-digit EPS growth after fiscal 2025. He added that this recovery is based on his belief in the company’s management and its ability to execute on its strategy. Sole noted that since Stefan Larsson became CEO in 2021, the company has standardized global operations, revamped products, marketing, and consumer experiences, and upgraded its supply chain. He added that these initiatives have paved the way for EPS expansion.

PVH Corp (NYSE:PVH) is a luxury fashion company that operates Tommy Hilfiger and Calvin Klein brands.